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MicroRNAs (miRNAs) are a class of small non-coding RNAs, typically 22 
nucleotides in length, which post-transcriptionally regulate gene expression. Mature 
miRNAs bind complementary sequences in the 3c untranslated region ƍ875RI 
target mRNAs and repress protein expression via a number of mechanisms 
including mRNA destabilisation and/or inhibition of translation [1]. So far, almost 
36,000 mature miRNAs from 223 species have been classified with 2588 of them 
human (miRBase, Release 21) [2, 3ƒ]. As a single miRNA is able to target hundreds 
of transcripts in humans, they are likely to influence regulation of all cellular events 
[4, 5] and their dysregulation has been correlated with disease pathogenesis [6].  In 
addition to acting endogenously, miRNAs can be released from cells where they 
may be involved in cell-cell communication and extracellular regulatory 
mechanisms and have been detected in many body fluids [7, 8]. These extracellular, 
circulating miRNAs may be non-invasive biomarkers of disease and targets for 
therapeutic intervention [9, 10]. 
 
Individual miRNAs have been found to regulate specific genes involved in lipid 
metabolism. He et al. [11]ƒƒ utilised target prediction to identify the possible 
regulation of lipoprotein lipase (LPL) by miR-590. They used synthetic miR-590 
miRNA with human THP-1 macrophages to demonstrate for the first time that miR-
590 may be involved in atherosclerosis by negatively regulating lipid accumulation, 
lipid-laden foam cell formation, and pro-inflammatory cytokine (including TNF-Į 
and IL-1ȕproduction via downregulation of LPL expression. In a related manner, 
it has been shown by Vickers et al. [12]ƒƒ that a single microRNA, miR-223, plays 
a critical role co-ordinating lipid metabolism by post-transcriptionally regulating 
multiple genes which control uptake, efflux, and biosynthesis of cholesterol. miR-
223 appears to achieve this through the downregulation of the expression of both 
Hmgcs1 (3-hydroxy-3-methylglutaryl-CoA synthase 1) and Scarb1 (scavenger 
receptor class B member 1), inhibiting cholesterol synthesis. miR-223 was also 
found to have an indirect effect on ABCA1 activity via a repression of Sp3 
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transcription factor. The expression of miR-223 was itself found to be linked with 
cholesterol levels, with decreased miR-223 transcription during cholesterol 
depletion, providing a case for its potential use in diagnostics as a circulating 
biomarker for altered cholesterol homeostasis. Cholesterol efflux, which has been 
regarded as an important cholesterol regulatory mechanism, has been shown in 
other studies to be controlled by miRNAs.  miR-33a and miR-33b, located within 
the intron of the sterol regulatory element-binding protein genes SREBF2 and 
SREBF1, coding for major transcription factors controlling cholesterol and fatty 
acid metabolism.  These are co-transcribed in cholesterol depleted conditions [13]. 
miR-33a is expressed in human macrophages and hepatocytes and regulates 
cholesterol efflux and HDL synthesis via gene repression of cholesterol transporter 
proteins including ABCA1 [14].  ABCA1 (ATP-binding cassette transporter 1), 
which contains putative binding sites for miR-33a and miR-E LQ LWV ƍ 875, 
mediates efflux of free cholesterol which then forms HDL and is of particular 
importance in lipid-laden macrophages (foam cells) for removal of excess 
cholesterol out of the cell by reverse cholesterol transport. Regulation of ABCA1-
targeting miRNAs holds great therapeutic potential in the treatment of 
atherosclerosis, via cholesterol homeostasis as small changes in their expression 
influences ABCA1 activity, in turn leading to large changes in HDL-cholesterol 
levels [15, 16] 
While our understanding of the roles of miRNA regulation in lipid metabolism 
rapidly grows, the practical use of this knowledge in the clinical application of 
treatments such as anti-miRs and miRNA-mimics for lipid disorders will experience 
the many challenges RNAi-based therapeutics face, including their need for targeted 
delivery and the avoidance of immune response activation [10].  
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microRNA target prediction tools. Frontiers in genetics 2014; 5:23.   
 This is an important review of the available computational analysis tools 
available for predicting miRNA sequences that have potential regulatory 
cross-disciplinary targets. 
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11 ƒƒ He PP, Ouyang XP, Tang YY et al. MicroRNA-590 attenuates lipid 
accumulation and pro-inflammatory cytokine secretion by targeting 
lipoprotein lipase gene in human THP-1 macrophages. Biochimie 2014; 
106:81-90. 
In this study the effects of miRNA-590 (thought to have protective actions 
in cardiovascular disease with an unknown target mechanism) were 
evaluated on the human monocytic cell line THP-1. The authors showed that 
miRNA-590 inhibited lipoprotein lipase activity and the production of pro-
inflammatory cytokines from these cells.  This also coincided with reduced 
lipid accumulation indicating a possible anti-atherosclerotic mechanism. 
 
12 ƒƒ Vickers KC, Landstreet SR, Levin MG et al. MicroRNA-223 coordinates 
cholesterol homeostasis. Proc Natl Acad Sci U S A 2014; 111:14518-14523. 
 This study focussed on miRNA-223 which has been linked to inflammatory 
responses.  The authors showed that miRNA-223 caused repression of the 
sterol enzymes 3-hydroxy-3-methylglutaryl-CoA synthase 1 and 
methylsterol monooxygenase 1 thereby inhibiting cholesterol synthesis. It 
was also able to indirectly increase cholesterol efflux. 
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Aƒ van Rooij E, Kauppinen S. Development of microRNA therapeutics is 
coming of age. EMBO Mol Med 2014; 6:851-64 
 This paper assesses the potential of miRNAs for the treatment of a wide 
variety of diseases ranging from chronic viral infection (hepatitis C virus)  
and cardiovascular disease to cancer. Different strategies for the modulation 
of miRNA activity are discussed such as miRNA mimics and antimiR 
oligonucleotides. 
 
Bƒ Daniel JM, Penzkofer D, Teske R et al. Inhibition of miR-92a improves re-
endothelialization and prevents neointima formation following vascular 
injury. Cardiovasc Res 2014; 103:564-72 
 This study investigated the role of miRNA-92a in vascular injury. The authors 
observed that miRNA-92a was upregulated following physically-induced 
damage to femoral arteries from mice.  They were also able to show that, 
using antisense locked nucleic acid to miRNA-92a, suppression of intimal 
lesions occurred as a result of accelerated re-endothelialisation uncovering a 
potential approach to the treatment of vascular injury. 
 
  
Cƒ [1] Kopke S, Buhrke T, Lampen A. miRNA Expression in Human Intestinal 
Caco-2 Cells is Comparably Regulated by cis- and trans-Fatty Acids. Lipids 
2015; 50:227-39. 
 This study set out to evaluate whether there were any differences in miRNA 
expression in response to either trans- or cis-fatty acids in cancer cells.  The 
authors investigated the expression of 84 cancer-related miRNAs in Caco-2 
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cells (colon cancer-derived).  They concluded that there was no bias toward 
either trans- or cis-fatty acids in 66 miRNAs that were deregulated by fatty 
acids. 
 
 
